Riskpilot← Back to searchSign inGet full accessAranda Pharma Oy
OYActiveY-tunnus 2712646-3Microkatu 1Research and experimental development on natural sciences and engineering · NACE 7210Est. 20152 employeeswww.arandapharma.com
Revenue 2024
EUR 13K
0% vs 2023
EBITDA margin
-1813.4%
0% vs 2023
Equity ratio
43.5%
Financial strength
Net profit 2024
EUR -249K
+13% vs 2023
| Revenue | EUR 13K | +0% |
| EBITDA | EUR -243K | +0% |
| Net profit | EUR -249K | +13% |
| Total assets | EUR 2,6M | -7% |
| Equity | EUR 1,1M | -15% |
| Employees | 2 | — |
Legal name
Aranda Pharma Oy
Y-tunnus number
2712646-3
Legal form
Osakeyhtiö
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
22. syyskuuta 2015
Share capital
EUR 2 500
Employees
2 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimialana on lääketieteellinen tutkimus ja kehitystyö ja muu siihen liittyvä tai sen yhteyteen soveltuva liiketoiminnan harjoittaminen. Edellä mainittuihin toimintoihin liittyvä vienti- ja tuontitoiminta.
Address
Microkatu 1
Phone
+3580440323361
Email
anu.muona@arandapharma.com
Website
www.arandapharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 13 | 13 |
| Staff expenses | −100 | −114 | −107 | −120 | −97 | −13 452 |
| EBITDA | −152 | −178 | −194 | −268 | −243 | −243 |
| Depreciation & amort. | −0 | −0 | −0 | — | −0 | −2 |
| EBIT | −153 | −179 | −194 | −268 | −243 | −243 |
| Net financials | −7 | −8 | −62 | −10 | −43 | −43 |
| Profit before tax | −159 | −186 | −256 | −278 | −286 | −249 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −159 | −186 | −256 | −278 | −286 | −249 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 2 038 | 2 086 | 2 592 | 2 394 | 2 764 | 2 565 |
| Equity | 1 220 | 1 033 | 1 476 | 1 198 | 1 312 | 1 115 |
| Long-term debt | 742 | 1 000 | 874 | 1 125 | 1 333 | 126 266 |
| Short-term debt | 76 | 53 | 242 | 71 | 119 | 18 785 |
| Total debt | 818 | 1 053 | 1 115 | 1 196 | 1 452 | 1 451 |
EBITDA margin
-1813.4%
This company
15.8%
Market median
-11577% vs market
20192024
Equity ratio
43.5%
This company
38.2%
Market median
+14% vs market
20192024
Return on equity
-22.4%
This company
18.4%
Market median
-222% vs market
20192024
Net profit margin
-1860.3%
This company
8.1%
Market median
-23067% vs market
20192024
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20192024
Debt / equity
1.30×
This company
0.62×
Market median
-110% vs market
20192024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via PRH / YTJ · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AM Confidential Clerk | Confidential Clerk | 2015 | — | — |
KM Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
HP Confidential Clerk | Confidential Clerk | 2015 | — | — |
EI | Audit | 2015 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairperson | 2021 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairperson | 2018 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Aranda Pharma Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anu Marketta Muona | Confidential Clerk | 0 companies |
| Kai Mika Petteri Käyhkö | Chief Executive Officer | 0 companies |
| Heikki Petter Eronen | Confidential Clerk | 0 companies |
| Elina Irja Anneli Laitinen | Audit | 0 companies |
| Mikko Lauri Sampsa Mannerkoski | Chairperson | 0 companies |
| Christoph Paul Josef Willers | Board of Directors | 0 companies |
| Aki Pellervo Prihti | Board of Directors | 0 companies |
| Milla Maria Koistinaho | Board of Directors | 0 companies |
| Erkki-Paavo Tenhunen | Board of Directors | 0 companies |
| Jyrki Pekka Sakari Mattila | Chairperson | 0 companies |